Galenicum obtains the approval of the DCP of Anagrelide
December 21, 2017
Galenicum received the approval of the DCP of Anagrelida on December 6th for several countries in Europe, including Germany, France, the Czech Republic, the Nordic countries and the UK.
The DCP was presented on November 21st, 2016 for these countries and in the coming months it is expected to obtain national authorizations.
Anagrelide is a drug used to treat the overproduction of blood platelets. It is also used in the treatment of chronic myeloid leukemia, a cancer of the blood in which the bone marrow produces too many granulocytes, a type of white blood cell.
Galenicum has signed agreements with several multinational companies in the industry to market this product. In this way, Galenicum expands its portfolio of antineoplastic and immunomodulatory drugs.